Haloperidol Lactate

Delirium, Schizophrenia, Schizophrenia + 9 more
Treatment
2 FDA approvals
20 Active Studies for Haloperidol Lactate

What is Haloperidol Lactate

HaloperidolThe Generic name of this drug
Treatment SummaryHaloperidol is a medication used to treat psychotic disorders like schizophrenia. It works by blocking dopamine receptors in the brain, reducing the overproduction of dopamine which is believed to cause these conditions. Haloperidol is generally effective and well-tolerated, and is one of the most commonly used antipsychotic medications worldwide. It is normally prescribed to treat “positive” symptoms of schizophrenia such as hallucinations, hearing voices, and disorganized speech. However, it can also cause side effects such as movement disorders, sedation, weight gain, and prolactin changes. Haloperidol has largely been replaced by newer
Haldolis the brand name
image of different drug pills on a surface
Haloperidol Lactate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Haldol
Haloperidol
1971
300

Approved as Treatment by the FDA

Haloperidol, otherwise known as Haldol, is approved by the FDA for 2 uses which include Gilles de la Tourette's Syndrome and Tourette Syndrome .
Gilles de la Tourette's Syndrome
Helps manage Gilles de la Tourette's Syndrome
Tourette Syndrome
Helps manage Gilles de la Tourette's Syndrome

Effectiveness

How Haloperidol Lactate Affects PatientsHaloperidol is an effective treatment for positive symptoms of schizophrenia, such as hearing voices or hallucinations. However, it can also cause serious side effects like movement disorders, sedation, weight gain, and changes in levels of the hormone prolactin. Haloperidol is more likely to cause these side effects than other similar drugs, but also works better for reducing schizophrenia symptoms. It works by affecting dopamine pathways in the brain that control symptoms and side effects. In some cases, haloperidol can cause serious and even potentially fatal conditions like Neuroleptic Malignant Syndrome (NMS), QT-prolongation, and
How Haloperidol Lactate works in the bodyHaloperidol works by blocking dopamine receptors in the brain. It is used for treating psychosis, as the overproduction of dopamine is linked to it. Haloperidol is a strong antagonist of the dopamine receptor D2, mainly in the mesolimbic and mesocortical systems of the brain. It also inhibits the effects of dopamine and increases its turnover. It binds more tightly than dopamine to the D2 receptor. It blocks post-synaptic dopamine (D2) receptors, eliminating dopamine neurotransmission and leading to relief from delusions and hallucinations. Haloperidol also has antiemetic activity and can cause extrapy

When to interrupt dosage

The quantity of Haloperidol Lactate is contingent upon the diagnosed situation, including Palliative Care, aggressive response and phencyclidine. The amount of dosage is outlined in the table below, based on the method of delivery.
Condition
Dosage
Administration
phencyclidine
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Obsessive-Compulsive Disorder
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Tourette Syndrome
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Nausea
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Schizophrenia
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Aggression
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Palliative Treatment
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Severe Disruptive Behaviour Disorders
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Huntington Disease
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Delirium
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
severe Hyperactivity
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Schizophrenia
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular

Warnings

Haloperidol Lactate Contraindications
Condition
Risk Level
Notes
Coma
Do Not Combine
Asthma
Do Not Combine
Parkinson's Disease
Do Not Combine
Mental Depression
Do Not Combine
Basal Ganglia Lesions
Do Not Combine
Mental Depression
Do Not Combine
There are 20 known major drug interactions with Haloperidol Lactate.
Common Haloperidol Lactate Drug Interactions
Drug Name
Risk Level
Description
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Haloperidol.
Amisulpride
Major
Haloperidol may increase the antipsychotic activities of Amisulpride.
Azelastine
Major
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Cariprazine
Major
The metabolism of Cariprazine can be decreased when combined with Haloperidol.
Eliglustat
Major
The metabolism of Eliglustat can be decreased when combined with Haloperidol.
Haloperidol Lactate Toxicity & Overdose RiskThe lowest toxic dose of this drug when taken orally by rats has been found to be 71mg/kg.
image of a doctor in a lab doing drug, clinical research

Haloperidol Lactate Novel Uses: Which Conditions Have a Clinical Trial Featuring Haloperidol Lactate?

285 active studies are presently investigating the utility of Haloperidol Lactate for the treatment of Obsessive-Compulsive Disorder, Palliative Care and Phencyclidine-related conditions.
Condition
Clinical Trials
Trial Phases
Obsessive-Compulsive Disorder
66 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 1, Early Phase 1
Schizophrenia
97 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2
Schizophrenia
32 Actively Recruiting
Early Phase 1, Not Applicable, Phase 4
Huntington Disease
5 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Aggression
1 Actively Recruiting
Not Applicable
Nausea
0 Actively Recruiting
Severe Disruptive Behaviour Disorders
1 Actively Recruiting
Phase 2
Tourette Syndrome
0 Actively Recruiting
Palliative Treatment
1 Actively Recruiting
Phase 3
Delirium
26 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 4, Early Phase 1
phencyclidine
0 Actively Recruiting
severe Hyperactivity
0 Actively Recruiting

Haloperidol Lactate Reviews: What are patients saying about Haloperidol Lactate?

4.3Patient Review
10/30/2011
Haloperidol Lactate for Delirium
I was put on hospice due to cancer and began using this drug. So far, it has given me the best results out of all the others.
2.3Patient Review
4/13/2013
Haloperidol Lactate for Aggressive Behavior
I was so angry after they gave me this shot. It did nothing to calm me down, if anything it made me more mad. I wouldn't recommend it to anyone.
2.3Patient Review
8/26/2009
Haloperidol Lactate for Schizophrenia
My daughter is still experiencing halucinations even though she's on a high dosage of the medication.
1Patient Review
2/27/2009
Haloperidol Lactate for Tourette's
My tourettes symptoms have gotten worse since I started this treatment. I've been having a lot of motor tics and screaming.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about haloperidol lactate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between haloperidol and haloperidol lactate?

"It can be taken orally as a tablet or concentrate, or as a nasal spray. It can also be given as an injection, either as a short-acting solution or as a long-acting preparation."

Answered by AI

Can Haldol make you lactate?

"For males, it may result in decreased sexual ability, inability to produce sperm, or enlarged breasts.

Despite the fact that many people using this medication don't experience serious side effects, there is still a possibility that haloperidol may increase prolactin levels in the body. This chemical increase can have different effects in males and females. For females, it may cause unwanted breast milk, missed or stopped periods, or difficulty getting pregnant. For males, it may lead to decreased sexual ability, infertility, or enlarged breasts."

Answered by AI

What is haloperidol lactate used for?

"Haloperidol is a psychiatric medication (antipsychotic type) that works by helping to restore the balance of certain natural substances in the brain. Haloperidol also can decrease hallucinations and help you to think more clearly and positively about yourself, feel less nervous, and take a more active part in everyday life. Haloperidol is not for use in psychotic conditions related to dementia. Haloperidol may also be used for purposes not listed in this medication guide.

50"

Answered by AI

How long does haloperidol lactate last?

"Haloperidol is a medication that is injected into a muscle usually every 3-4 weeks."

Answered by AI

Clinical Trials for Haloperidol Lactate

Image of Baylor College of Medicine in Houston, United States.

Stepped Care Treatment for Anxiety

7 - 17
All Sexes
Houston, TX
Childhood anxiety disorders (CAD) are common and impairing. Family based cognitive behavioral therapy (CBT) is efficacious in treating CAD. Yet, many children do not receive care due to barriers such as limited provider availably, high treatment costs, and constrained family resources (e.g., time). To combat these barriers, other treatment methods have been developed. The stepped care treatment models maximize resources by providing low-intensity, low-cost interventions as a first time treatment, while stepping up care for those needing more intensive treatment. Specifically, a stepped care model for CAD that begins with a parent-focus intervention has great promise to deliver efficacious and cost-effective treatment without having to engage the child. While stepped care approaches show promise in treating CAD with comparable efficacy to standard CBT, there remains a large research-to-practice gap. The stepped care model for CAD that begins with a parent-focused intervention has yet been explored, and very little is known about intervention mediators that explain mechanisms of change. This research is being done to improve the reach and quality of services using a stepped care model, offering an affordable and practical solution to the widespread gap in youth mental health care.
Waitlist Available
Has No Placebo
Baylor College of Medicine
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Have you considered Haloperidol Lactate clinical trials? We made a collection of clinical trials featuring Haloperidol Lactate, we think they might fit your search criteria.Go to Trials
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Brain Stimulation for Cannabis Craving in Schizophrenia

18 - 65
All Sexes
Nashville, TN
The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cue-induced craving and cognitive performance in individuals with schizophrenia and schizoaffective disorder, while targeted stimulation of the L DLPFC leads to these changes in healthy controls who use cannabis. This study will test a model that integrates brain network pathophysiology and cognition to 1) explain the prevalence of cannabis use in schizophrenia and 2) identify a target for engagement in schizophrenia. This study seeks to establish a neuroscientific framework to guide future treatment-oriented studies aimed at reducing craving and improving cognitive performance in individuals with schizophrenia and schizoaffective disorder. This is a study of the effect of 2 rTMS interventions on functional connectivity and craving in individuals with schizophrenia or schizoaffective disorder and healthy controls who use cannabis. Aim 1: Target Engagement: Determine if rTMS manipulates functional connectivity of each target (DMN, L DLPFC) (n=100). Aim 2: Clinical Efficacy: Determine if rTMS affects cue-induced craving and if craving change correlates with change in functional connectivity (n=100). As an exploratory analysis, the factors that explain individual variance in rTMS-induced connectivity change will also be explored.
Waitlist Available
Has No Placebo
Vanderbilt Psychiatric Hospital
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Repetitive Transcranial Magnetic Stimulation for Schizophrenia

18 - 65
All Sexes
Nashville, TN
The central hypothesis is this: DMN connectivity can be modulated with inhibitory cTBS when delivered on an accelerated treatment schedule. This study seeks to provide evidence that accelerated, network-targeted inhibitory stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cognitive performance in individuals with schizophrenia and schizoaffective disorder. This study will also compare the effect of inhibitory cTBS in healthy individuals, as it may also lead to both altered network activity and a behavioral change in cognitive performance in individuals without schizophrenia or schizoaffective disorder. If successful, this study will have identified a safe, effective, and broadly applicable treatment for cognitive impairment in schizophrenia that has potential for translation into many other psychiatric and neurodevelopmental disorders, such as autism.
Waitlist Available
Has No Placebo
Vanderbilt Psychiatric HospitalHeather Ward, MD
Have you considered Haloperidol Lactate clinical trials? We made a collection of clinical trials featuring Haloperidol Lactate, we think they might fit your search criteria.Go to Trials
Image of Woodland International Research Group /ID# 275747 in Little Rock, United States.

Emraclidine for Schizophrenia

18 - 65
All Sexes
Little Rock, AR
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 258 participants will be enrolled across roughly 32 sites in the United States. Participants in Part A will be assigned to one of multiple ascending doses of emraclidine or placebo administered orally for 14 days or up to 21 days. Participants in Part B will receive Emraclidine or placebo administered orally for up to 42 days. Participants will be followed for 30 days after the last dose of the study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Phase 2
Recruiting
Woodland International Research Group /ID# 275747 (+4 Sites)ABBVIE INC.AbbVie
Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Focused Ultrasound for Anorexia

18 - 65
All Sexes
Toronto, Canada
The goal of this clinical trial is to evaluate the safety and initial clinical effectiveness of MRI-guided focused ultrasound (MRgFUS) thermal ablation (capsulotomy) in patients with treatment-refractory anorexia nervosa (AN) and comorbid obsessive-compulsive disorder (OCD) and major depressive disorder (MDD). The main questions it aims to answer are: 1. Can MR-guided focused ultrasound capsulotomy be safely delivered through an intact skull in patients with treatment-refractory anorexia nervosa and comorbid OCD and/or MDD, with a safety and side-effect profile comparable to traditional radiofrequency neurosurgical approaches? 2. Does MRgFUS capsulotomy produce clinical outcomes comparable to open surgical ablative procedures-specifically, improvements in anxiety, mood, quality of life, anorexia nervosa psychopathology, habit formation, and weight-in patients with treatment-refractory anorexia nervosa? Participants will: 1. Undergo baseline imaging and clinical assessments 2. Receive a single MRgFUS capsulotomy targeting the ALIC 3. Be monitored for 24 months post-treatment to assess adverse events, quality of life, and symptom changes using standardized clinical and neuropsychiatric measures
Phase 1
Recruiting
Sunnybrook Health Sciences Centre
Have you considered Haloperidol Lactate clinical trials? We made a collection of clinical trials featuring Haloperidol Lactate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security